Market Overview

Recap: Reata Pharmaceuticals Q3 Earnings

Share:

 

Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 0.76% over the past year to ($1.31), which beat the estimate of ($1.98).

Revenue of $1,401,000 declined by 83.00% year over year, which beat the estimate of $1,270,000.

Guidance

Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/z6fgbcwf

Technicals

Company's 52-week high was at $257.96

Company's 52-week low was at $88.17

Price action over last quarter: Up 49.61%

Company Profile

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

 

Related Articles (RETA)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com